Boston Scientific (NYSE:BSX) is classified as a constituent of the 170 company Medical Specialties GICS industry group, which is a segment of the 656 company GICS Health Technology sector. The market value of BSX is $35.6 billion which falls in the top 10% of its industry group. Portfolio Grader's current ranking for BSX puts it 64 among the 170 companies in this industry group, putting it in the second quartile; in the top half of the sector with a ranking of 223 among the 656 companies in the sector, and number 1,662 in the nearly 5,000 company Portfolio Grader universe.

The current recommendation of Buy for Boston Scientific (NYSE:BSX) has been derived by using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing methodology. This represents no change from the previous week and is the same ranking BSX has had from Portfolio Grader for 3 months.

The current recommendation of Buy for Boston Scientific (NYSE:BSX) is derived using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. BSX has maintained this ranking for 3 months.

With a $39.3 billion market value, Boston Scientific (NYSE:BSX) ranks in the top decile in its industry group, Health Care Equipment & Supplies, and in the top 10% of its sector group, Health Care, in market value. From the prospective of investment attractiveness, the stock's Portfolio Grader ranking places it 37 among the 161 companies in this industry group, putting in the top quartile; in the top quartile of the sector with a ranking of 125 among the 781 companies in the sector, and number 802 in the nearly 5,000 company Portfolio Grader universe.

Boston Scientific (NYSE:BSX) is a $38.8 billion in market value member of the Health Care Equipment & Supplies GICS industry group where the stock's Portfolio Grader ranking places it 38 among the 161 companies in this industry group, placing it among the leaders. BSX is ranked in the top quartile of the sector with a ranking of 125 among the 781 companies in the sector and number 812 in the 5000 company Portfolio Grader company universe.

Currently, Boston Scientific (NYSE:BSX) has a Buy using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing approach. BSX has maintained this ranking for 2 months.

With a $38.2 billion market value, Boston Scientific (NYSE:BSX) ranks in the top decile in its industry group, Health Care Equipment & Supplies, and in the top decile of sector group, Health Care, in market value. From the viewpoint of investment attractiveness, the stock's Portfolio Grader ranking places it 39 among the 164 companies in this industry group, giving it a well above-average position; in the top quartile of the sector with a ranking of 127 among the 785 companies in the sector, and number 793 in the nearly 5,000 company Portfolio Grader universe.

Boston Scientific (NYSE:BSX) is ranked as a Buy using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. This represents no change from the previous week and is the same ranking BSX has had from Portfolio Grader for the last month.

Boston Scientific (NYSE:BSX) is classified as a constituent of the 163 company Health Care Equipment & Supplies GICS industry group, which is a segment of the 782 company GICS Health Care sector. BSX has a market value of $40.7 billion which is in the top decile in its industry group. Portfolio Grader's current ranking for BSX puts it 39 among the 163 companies in this industry group, putting in the top quartile; in the top quartile of the sector with a ranking of 105 among the 782 companies in the sector, and number 781 in the nearly 5,000 company Portfolio Grader universe.

Portfolio Grader currently ranks Boston Scientific (NYSE:BSX) a Buy. With exclusive fundamental and quantitative metrics developed by Louis Navellier, this analytical tool assesses nearly 5,000 stocks weekly. This represents no change from the previous week and is the same ranking BSX has had from Portfolio Grader for the last month.

Portfolio Grader currently ranks Boston Scientific (NYSE:BSX) a Hold. The methodology for fundamental and quantitative metrics used in this analytical tool, developed by Louis Navellier researches and ranks nearly 5,000 stocks each week. BSX has maintained this ranking for 2 months.